14 June 2016 | New opportunities with advanced viral vector technologies for novel therapies & vaccines
SIRION Biotech CEO to present to Europe's Investment Professionals in Frankfurt
- Picture by Michael Kolb, DVFA
29 January 2016 | Matured vector technologies open industrial gene-therapy and vaccine markets to German Biotech
Viral Vectors gain traction in the industryMunich, Germany January 29, 2016 - Last year was pivotal for German gene delivery expert SIRION Biotech. As global specialists for refining viral vectors, the company was able to strike major deals with industrial partners and altogether almost double their annual revenue stream. The company was further able to efficiently upscale and validate their in-house adenovirus serotype Ad19a as a potential gene vector for vaccination development....more.
27 April 2015 | Viral Vector Technologies from Europe directly accessible in Boston
27 April 2015 | Virale Vektortechnologien aus Deutschland nun auch am US-Markt
24 June 2014 | SIRION Biotech participates in Gene Therapy Expert Panel Discussion at the Piper Jaffray GenomeRx Symposium
New York City, more...
04 March 2014 | SIRION Biotech presents at SACHS Forum in Zurich, the 7th Annual European Life Science CEO Forum for Partnering & Investing
17 February 2014 | Horizon Discovery Signs Supply and Distribution Agreement with SIRION Biotech
Agreement adds SIRION’s custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering
Munich, Cambridge, UK, Horizon Discovery™ (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a supply and distribution agreement with SIRION Biotech GmbH (SIRION). Under the terms of the agreement Horizon’s customers can now access SIRION’s highly efficient RNAiONE custom shRNA development services, as well as SIRION’s off-the-shelf validated shRNA and cDNA over-expression reagents. Through this partnership Horizon now offers a full spectrum of gene modulation technologies ranging from stable shRNA knockdown and cDNA overexpression systems to the ability to edit endogenous genes.
09. April 2013 | Viral vectors for novel cell models, gene therapy and vaccine development gain further funds from private investors
SIRION Biotech GmbH closes new financing round with additional investors
Munich,Germany, SIRION Biotech GmbH has won two additional private investors, one of them being Aumenta GmbH. Both contribute to a large extent to the current financing round side by side with the existing investors Creathor Venture, HTGF, Bayernkapital and KfW, next to the Managing Directors. The new funds will further strengthen access to the Japan and USA markets and drive the evaluation of clinical programs for viral vectors and commercial projects for novel cell models. The laboratories in Munich will be expanded by GLP facilities (Good Laboratory Practice).
July 10, 2012 | SIRION Biotech presents at prestigious World Summit on Innovation in Boston, MA on 26 September 2012
Munich, Germany,SIRIONBiotech is invited to present its business model and its recent history of success at the World Summit on INNOVATION & ENTREPRENEURSHIP in Boston on 26 – 28 September 2012: “The Summit sets the scene for some of the world’s eminent dreamers and doers to plot the new frontier of the smarter innovation economy” (http://www.thewsie.org/prologue.html). The World Summit on Innovation & Entrepreneurship was launched in 2006 at the United Nations under the support of three UN agencies, International Chamber of Commerce, African Union, in partnership with key multinationals like PepsiCo, Cisco, La Post, Boeing, Microsoft, CNBC, and Business Week.
JUNE 27, 2011 | Creathor Venture accelerates growth of SIRION BIOTECH with further investment
Creathor Venture and current investors invest in SIRION BIOTECH and provide further funding. In addition to Creathor Venture the investors High-Tech-Gründerfonds, KfW, and Bayernkapital also joined the current round to further fund the young Munich based biotech. SIRION's core competence lies in the development and marketing of adenoviral and lentiviral vector technologies in the field of target validation.
Nov 2009 | SIRION BIOTECH receives growth financing from Creathor Venture, Bayernkapital, KFW and High-Tech-Gründer-Fonds (HTGF)
The funding will help SIRION BIOTECH to enhance their activities in foreign markets and to accelerate the speed of developing products in the area of adenovirus vector technology.
Oct 2009 | SIRION BIOTECH together with Helmholtz Zentrum Munich (HGMU) receives funding from BMWi for finding new therapeutic approaches in leukemia
In the two years cooperation project funded with approx. EUR 300 T SIRION BIOTECH will facilitate viral delivery of siRNAs to hematopoietic cells which HGMU will use for target validation in leukemia research.
Nov 2008 | SIRION BIOTECH receives a financing from Clusterfond Start up! of Bayernkapital with Creathor Venture and KFW being co-investors
After having received a High Tech Gründerfond (HTGF) financing in 2007 the company has approved the market acceptance of their services and products in the sector of genetically modified cells and vector systems. The new financing round with Clusterfond Start up! being in the lead investor is intended for accelerating the pace of the market entry.
SEP 2007 | SIRION GmbH raised an early-stage funding from High-Tech-Gruenderfonds
SIRION GmbH, a supplier of tools & services for RNAi-based functional gene analysis, raised an early-stage funding from High-Tech-Gründerfonds, Bayernkapital and Creathor Venture.
NOV 2006 | SIRION started in new laboratories
SIRION started in new laboratories in IZB in Martinsried its service and product business in providing gene function tools.
JUN 2006 | SIRION GmbH was one of the winners of business plan competition.
SIRION GmbH was one of the winners of the Science4life business plan competition.
JUN 2006 | SIRION GmbH filed patent
SIRION GmbH filed patent for its proprietary Q-tech technology.
DEZ 2005 | Formation of SIRION GmbH
SIRION GmbH was founded in Munich as a biotech company for innovative services and products for gene silencing and customized gene expression solutions.